FSD Pharma Inc. (HUGE): Price and Financial Metrics
GET POWR RATINGS... FREE!
HUGE Stock Price Chart Interactive Chart >
HUGE Price/Volume Stats
| Current price | $0.78 | 52-week high | $1.94 |
| Prev. close | $0.79 | 52-week low | $0.69 |
| Day low | $0.76 | Volume | 38,300 |
| Day high | $0.80 | Avg. volume | 132,078 |
| 50-day MA | $0.91 | Dividend yield | N/A |
| 200-day MA | $1.09 | Market Cap | 31.55M |
FSD Pharma Inc. (HUGE) Company Bio
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.
Latest HUGE News From Around the Web
Below are the latest news stories about FSD Pharma Inc that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
FSD Pharma Unveils Newly Designed WebsiteThis post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. FSD Pharma (NASDAQ: HUGE ) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the launch of its newly designed website . According to the update, the new site conveys the companys emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeutics, said Anthony Durkacz, interim CEO of FSD Pharma. With some of the greatest min... |
FSD Pharma Announces Launch of New Corporate WebsiteNew Website Shares FSD''s Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders FSD Pharma Inc. (NASDAQ: HUGE ) (CSE: HUGE ) (FRA: 0K9A) (" FSD Pharma " or the " Company "), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. The new site conveys the Company''s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. To view the website, please visit www.fsdpharma.com . "We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeut... |
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of CanadaTORONTO, January 18, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, warmly congratulates Eleanor N. Fish, Ph.D., a member of its Research and Clinical Advisory Board, on her appointment to the Order of Canada. |
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13thTORONTO, January 04, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright Bioconnect Conference to be held virtually on January 10-13, 2022. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET on January 10 |
FSD Pharma Announces Share Repurchase ProgramTORONTO, December 30, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that its Board of Directors has authorized the repurchase by the Company of up to 2,000,000 of its Subordinate Class B Voting Shares (the "Subordinate Voting Shares") from time to time over the next 12 months at prevailing market prices in order to allow the Company to |
HUGE Price Returns
| 1-mo | -24.27% |
| 3-mo | -10.34% |
| 6-mo | -25.71% |
| 1-year | -54.65% |
| 3-year | -96.89% |
| 5-year | N/A |
| YTD | -23.53% |
| 2021 | -34.62% |
| 2020 | -71.26% |
| 2019 | -87.37% |
| 2018 | 755.60% |
| 2017 | -49.90% |
Loading social stream, please wait...